Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:investor
|
| gptkbp:acquiredBy |
gptkb:The_Carlyle_Group
|
| gptkbp:acquisitionYear |
2022
|
| gptkbp:focusesOn |
life sciences investments
biotechnology investments medical technology investments |
| gptkbp:foundedIn |
1973
|
| gptkbp:headquartersLocation |
gptkb:London,_United_Kingdom
|
| gptkbp:investedIn |
early-stage companies
late-stage companies |
| gptkbp:notableInvestment |
gptkb:Alnylam_Pharmaceuticals
gptkb:Solexa gptkb:Astex_Pharmaceuticals gptkb:Avillion gptkb:Clovis_Oncology |
| gptkbp:officeLocation |
gptkb:Boston,_United_States
gptkb:Cambridge,_United_Kingdom gptkb:Menlo_Park,_United_States |
| gptkbp:website |
https://www.abingworth.com/
|
| gptkbp:bfsParent |
gptkb:Scorpion_Therapeutics
|
| gptkbp:bfsLayer |
7
|
| https://www.w3.org/2000/01/rdf-schema#label |
Abingworth
|